TR-Dizin İndeksli Yayınlar Koleksiyonu
Permanent URI for this collectionhttps://hdl.handle.net/11727/4808
Browse
18 results
Search Results
Item Evaluation Of Demographic And Clinical Characteristics Of Female Patients Presenting With MINOCA And Differences Between Male Patients: A Subgroup Analysis Of MINOCA-TR Registry(2022) Gok, Gulay; Coner, Ali; Cinar, Tufan; Kilic, Salih; Yenercag, Mustafa; Oz, Ahmet; Ekmekci, Cenk; Ozluk, Ozlem; Zoghi, Mehdi; Ergene, Asim Oktay; Turk, Ugur Onsel; 35197228Objective: Although the prevalence and rate of myocardial infarction with non-obstructive coronary arteries (MINOCA) are higher in women than in men in previous cohorts, potential demographic and clinical differences between women who are diagnosed with MINOCA versus myocardial infarction with obstructive coronary arteries (MIOCA) have not been studied till date. In this study, we aimed to document these characteristics and to compare them between female patients with MINOCA and MIOCA. Methods: The study was a subgroup analysis of the MINO-CA-TR study. The study was a multi-center, observational cohort study that was conducted in Turkey between March 2018 and October 2018. In this study, 477 (29.3%) female patients who had been diagnosed with acute myocardial infarction were evaluated. Results: Of these women, 49 (10.3%) were diagnosed with MINOCA (mean age 58.9 +/- 12.9 years) and 428 (89.7%) had a final diagnosis of MIOCA (mean age 67.4 +/- 11.8 years). The prevalence of hypertension, hyperlipidemia, and diabetes mellitus was significantly lower in the MINOCA group than in the MIOCA group. In addition, the MINOCA group had higher rates of recent flu history and non-ST elevation myocardial infarction (NSTEMI) presentation than the MIOCA group. There were significant clinical differences in patients with MINOCA in terms of sex. The female patients were older, had higher systolic blood pressures, and lower hemoglobin levels than male patients. Conclusion: The study revealed that the prevalence of traditional coronary artery disease risk factors was lower in female patients with MINOCA than in those who had final diagnosis of MIOCA.Item Answer Regarding: Potent P2Y12 Inhibitors and Bleeding Complications(2022) Akinci, Sinan; Coner, Ali; Akbay, Ertan; Adar, Adem; Muderrisoglu, Haldun; 36200724Item Efficacy and Safety of Switching from Clopidogrel to Ticagrelor at the Time of Discharge in STEMI Patients Treated with a Pharmacoinvasive Approach(2021) Coner, Ali; Muderrisoglu, İbrahim Haldun; 0000-0002-5711-8873; ABD-7321-2021Objective: The aim of the study was to search for the efficacy and safety of switching from clopidogrel to ticagrelor at the time of discharge in ST-segment elevation myocardial infarction (STEMI) patients treated with a pharmacoinvasive approach. Materials and Methods: STEMI patients who were managed with pharmacoinvasive approach were involved in the study population. Patients were divided into two groups as clopidogrel and ticagrelor depending on the choice of P2Y12 inhibitor at the time of discharge. All-cause mortality, stent thrombosis, recurrent myocardial infarction, need for target lesion revascularization, and any major bleeding (BARC classification >= 2) were defined as composite clinical end points at the end of the 12th month follow-up. Results: A total of 194 patients (male: 156 patients, 80.4%; mean age 60.2 +/- 11.5 years) were involved in the study population (130 clopidogrel and 64 ticagrelor patients). The median time interval for switching time to ticagrelor was 48 (48-72) h. In a subgroup analysis for patients with a stented segment >= 30 mm, discharge with clopidogrel was related to 6.9 times increase in composite end points compared to patients discharged with ticagrelor (odds ratio: 6.955, confidence interval 95%: 1.512-30.980, p=0.012). Conclusion: Switching from clopidogrel to ticagrelor at the 48th h following fibrinolytic administration had similar safety end points in STEMI patients managed with pharmacoinvasive approach. In a subgroup of study patients with a total stent length of >= 30 mm, switching to ticagrelor was found to be superior to clopidogrel regarding composite clinical end points.Item Impact of the Novel Coronavirus Disease 2019 (COVID-19) Pandemic on Cardiac Emergencies and Future Perspectives in Turkey(2021) Coner, Ali; Kayipmaz, Afin Emre; Celikel, Elif; 0000-0002-5711-8873; ABD-7321-2021SARS-CoV-2-associated COVID-19 pandemic has affected the daily life of people across the world in 2020. Data about the course of viral involvement continues to be accumulated. COVID-19 is a multi-systemic disease, and the clinical presentations and possible complications may vary widely in different patient groups. The cardiovascular system is a primary target of COVID-19, and direct or indirect effects of viral involvement are observed. In addition to the direct effects of viral involvement on the cardiovascular system, decrement in acute cardiac emergencies has been experienced in many cardiology clinics in Turkey during the pandemic. Moreover, there may be a possible increase in out-of-hospital cardiac arrests in the near future. In this narrative review, we aimed to discuss the cardiac manifestations of COVID-19, the possible drug interactions related to the drugs used for COVID-19 management, and the effect of the pandemic on cardiac emergencies. We believe that understanding the natural mechanism of cardiac involvement of SARS-CoV-2 and emphasizing the data about out-of-hospital arrests will help clinicians effectively deal with the preventable cardiovascular causes of death in the forthcoming waves of COVID-19.Item New Oral AntiCoagulant Use in REnal Disease and AF (NOACURE-AF) Where do we stand? An expert consensus view using the Delphi method(2021) Coner, Ali; 0000-0002-5711-8873; 34623306; ABD-7321-2021Item In-Hospital Cardiac Complications in Legionnaires' disease: A Single Center Experience of 32 Patients(2021) Akinci, Sinan; Coner, Ali; 0000-0001-5250-5404; 0000-0002-5711-8873; AAD-5564-2021; ABD-7321-2021Introduction: Legionella species frequently causes Legionnaires' disease (LD), a community-acquired pneumonia (CAP). Although data on cardiac events during the course of CAP can be found in the literature, there has been little research on the same issue in LD patients specifically. This study aimed to investigate cardiac complications in the course of LD. Materials and Methods: A total of 32 patients hospitalized with CAP and who received a definitive diagnosis of Legionella infection were identified from the hospital database and included in the study population. The patients' electronic and written records were evaluated for possible cardiac complications. Results: Mean age was 65 +/- 13.5 years and 50% of the subjects were males. Seven patients died during hospitalization. Cardiovascular events were detected in 11 patients. New-onset atrial fibrillation was the most frequent event and was detected in 8 patients (25%), while two patients experienced a myocardial infarction, and one patient was diagnosed with myocarditis. The cardiovascular events were significantly related to the pneumonia severity index (PSI) score and need for intensive care unit. Conclusion: Although LD rarely involves the heart, it can often cause cardiac complications, and the frequency increases in parallel with the severity of the disease. This study indicates that patients with LD should be carefully followed for possible cardiac complications.Item Management of Sacubitril/Valsartan Combination in an End-stage Heart Failure Patient Hospitalized for COVID-19 Pneumonia: Should we Withdraw Temporarily or Continue?(2021) Coner, Ali; Altin, CihanBackground: Many factors were blamed for the worse prognosis in COVID-19. Heart failure patients are thought to be under increased risk because of either immune-compromised basal status or possible interaction of viral infection with on-going medications, such as the Renin-Angiotensin-Aldosterone system (RAAS) blockers. Sacubitril is a neprilysin inhibitor and its' combination with valsartan is recommended as a novel medication for heart failure. Case Report: A 71 years of age female with end-stage heart failure was hospitalized for COVID-19 pneumonia. She was under sacubitril/valsartan combination for the heart failure, and at the end of the first week of hospitalization, clinical and laboratory parameters recovered uneventfully. Sacubitril/valsartan therapy was continued without complications during the in-hospital course. Conclusion: Specific therapies for heart failure should not be withdrawn in COVID-19. To our knowledge, this is the first case report documenting the clinical progress of a COVID-19 pneumonia patient who was already under sacubitril/valsartan treatment.Item Pheochromocytoma: An overlooked reversible cause of heart failure with reduced ejection fraction(2021) Coner, Ali; Ozyildiz, Ali Gokhan; 0000-0002-5711-8873; 34523598; ABD-7321-2021Pheochromocytoma is a rare, benign tumor of adrenal medulla, and its clinical symptoms are related to catecholamine production. Clinical presentation may vary in a broad spectrum. Dilated or hypertrophied cardiomyopathies are the possible clinical outcomes of pheochromocytoma. Pheochromocytoma should be kept in mind in the differential diagnosis where resistant hypertension, palpitations, headache, and sweating accompany cardiomyopathy. Excessive adrenergic stimulation causing catecholamine discharge can trigger hypertension crisis, pulmonary edema, and myocardial necrosis. Here in this report, we aimed to present the case of a patient with pheochromocytoma related cardiomyopathy who was totally recovered after surgical excision of the tumor.Item Admission Tpe interval predicts reperfusion success in STEMI patients treated with fibrinolytic agents(2020) Coner, Ali; Akinci, Sinan; Akkucuk, Mehmet Husamettin; Altin, Cihan; Muderrisoglu, Haldun; 0000-0002-9635-6313; 0000-0003-4569-1143; 0000-0001-5250-5404; 31974326; AAG-8233-2020; AAJ-2828-2021; AAD-5564-2021Objective: Myocardial infarction is a leading cause of morbidity and mortality. Fibrinolytic administration is still a life-saving choice in ST-segment elevated myocardial infarction (STEMI), but the rate of successful reperfusion can be inconsistent. Failed reperfusion adds additional clinical risks to rescue percutaneous coronary intervention for STEMI patients. The interval between the peak of the T wave and the end of the T wave (Tpe) and the ratio of Tpe and a corrected measurement of the time from the start of the Q wave to the end of the T wave (Tpe/QTc ratio) are relatively new electrocardiogram (ECG) indices and have not yet been tested in STEMI patients treated with fibrinolytic agents. Methods: A total of 177 STEMI patients (mean age: 60.5 +/- 11.1 years; 138 men and 39 women) were enrolled in this retrospective study to evaluate ECG parameters. The Tpe interval and the Tpe/QTc ratio at baseline and at the 90th minute following the administration of fibrinolytic therapy were analyzed. The clinical and ECG findings of successful and failed reperfusion groups were compared. Results: Successful reperfusion was achieved in 119 patients (67.2%). The average Tpe interval on the admission ECG was shorter (91.7 vs. 100.9 milliseconds [ms]) (p<0.001) and shortened more in the successful reperfusion group (9.3 vs. 4.5 ms) (p<0.001). A cut-off value of 89.0 ms for the Tpe interval on the admission ECG was found to be related to reperfusion success with a sensitivity of 90.9%. Conclusion: The Tpe interval was a predictor for reperfusion success in STEMI patients treated with fibrinolytic agents.Item Salusin beta, atherosclerosis, and coronary slow flow(2020) Akinci, Sinan; Coner, Ali; 0000-0001-5250-5404; 32011318; AAD-5564-2021